<DOC>
	<DOC>NCT01788722</DOC>
	<brief_summary>The objective of the study is to investigate and collect post marketing data on the safety and efficacy of Visanne at follow-up visit after about 6 months of treatment and - for a subset of patients - at optional long-term follow-up visit after about 1 year of treatment under daily practice treatment conditions in Korean women and to obtain data on drug utilization on treatment for endometriosis.</brief_summary>
	<brief_title>Regulatory Post Marketing Surveillance Study in Korea</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<criteria>Signed and dated informed consent Women diagnosed by a physician as having endometriosis Women who are prescribed Visanne(dienogest 2mg)for the first time during the study period All contraindications according to the local marketing authorization have to be considered.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>